

Primary Efficacy and Safety of Mirikizumab in Moderate to Severe Crohn's Disease: Results of the Treat-Through VIVID 1 Study

Marc Ferrante,¹ Silvio Danese,² Minhu Chen,³ Geert D'Haens,⁴ Subrata Ghosh,⁵ Tadakazu Hisamatsu,⁶ Vipul Jairath,⁷ Jaroslaw Kierkus,⁸ Laurent Peyrin-Biroulet,⁹ Britta Siegmund,¹⁰ Sonja Michelle Bragg,¹¹ Wallace Crandall,¹¹ Theresa Hunter Gible,¹¹ Zhantao Lin,¹¹ Michelle Ugolini Lopes,¹¹ Nathan Morris,¹¹ Hilde Carlier,¹¹ Bruce E. Sands¹² for the VIVID Study Group

¹Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium; ²Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; ³Division of Gastroenterology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; ⁴Inflammatory Bowel Disease Center, Amsterdam University Medical Center, Amsterdam, Netherlands; ⁵APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland; ⁶Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan; ⁷Division of Gastroenterology, Department of Medicine, University Hospital, London, Canada; ⁸Division of Epidemiology and Biostatistics, Western University, London, Canada; ⁹Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland; ¹⁰Department of Gastroenterology, CHRU-Nancy, University of Lorraine, and University of Lorraine, INSERM, NGERE, Nancy, France; ¹¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, Berlin, Germany; ¹²Eli Lilly and Company, Indianapolis, USA; ¹³Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA



Disclosures (1/2)

- M. Ferrante** has received research grants from: AbbVie, Biogen, EG Pharma, Janssen, Pfizer, Takeda, and Viartis; received consulting fees from: AbbVie, AgomAb Therapeutics, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly and Company, Janssen Cilag, Merck Sharp & Dohme, MRM Health, Pfizer, Takeda, and Thermo Fisher Scientific; and received speaker's fees from: AbbVie, Biogen, Boehringer Ingelheim, Dr. Falk Pharma, Ferring Pharmaceuticals, Janssen Cilag, Merck Sharp & Dohme, Pfizer, Takeda, Truvion Healthcare, and Viartis; **S. Danese** has received consulting fees from: AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr. Falk Pharma, Eli Lilly and Company, Entera, Ferring Pharmaceuticals, Gilead Sciences, Hospira, Inotrem, Janssen, Johnson & Johnson, Merck Sharp & Dohme, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Takeda, TiGenix, UCB Pharma, and Vifor Pharma; and received lecture fees from: AbbVie, Amgen, Ferring Pharmaceuticals, Gilead Sciences, Janssen, Mylan, Pfizer, and Takeda; **M. Chen** has received speaker's fees from: AbbVie, AstraZeneca, China Medical System Holding Limited, Ipsen, Johnson & Johnson, and Takeda; **G. D'Haens** has been an advisor for: AbbVie, Ablynx, Active Biotech, AgomAb Therapeutics, Allergan, AlphaBionics, AM-Pharma, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, AstraZeneca, Avaxia Biologics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb/Celgene, Celltrion, Cosmo Pharmaceuticals, Dr. Falk Pharma, DSM Pharma Solutions, Echo Pharmaceuticals, Eli Lilly and Company, enGene, Exelium Biosciences, Ferring Pharmaceuticals, Galapagos NV, Genentech/F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Immunic Therapeutics, Johnson & Johnson, Kintai Therapeutics, Lycera, Medimetrics, Medtronic, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma, Mundipharma, Nextbionics, Novo Nordisk, Otsuka, Pfizer, PhotoPills, ProCiseDx, ProDigest, Progenity, Prometheus Laboratories/Nestlé, Protagonist Therapeutics, RedHill, Roberts Clinical Trials, Salix Pharmaceuticals, Samsung Bioepis, Sandoz, Seres Therapeutics/Nestec/Nestlé, Setpoint Medical, Shire, Takeda, Teva, TiGenix, Tillotts Pharma AG, Topivert, Versant, and Vifor Pharma; and received speaker's fees from: AbbVie, Biogen, Ferring Pharmaceuticals, Galapagos NV/Gilead Sciences, Johnson & Johnson, Merck Sharp & Dohme, Millenium/Takeda, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Tillotts Pharma AG, and Vifor Pharma; **S. Ghosh** has received research grants from: Eli Lilly and Company; been a member of steering committees for: AbbVie and Bristol Myers Squibb; and received consulting fees from: AbbVie, Celltrion, Ferring Pharmaceuticals, Galapagos NV, Janssen, Pfizer, and Takeda; **T. Hisamatsu** has received lecture fees from: AbbVie, EA Pharma, Gilead Sciences, Janssen Pharmaceutical K.K., JIMRO, Kyorin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer, and Takeda; received honoraria as an advisory board member/consultant from: AbbVie, EA Pharma, Eli Lilly and Company, Gilead Sciences, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Pfizer, and Takeda; and received pharmaceutical/research grants from: AbbVie, Alfresa Pharma, Daiichi Sankyo, EA Pharma, JIMRO, Kyorin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nichi-Iko Pharmaceutical, Nippon Kayaku, Pfizer, Takeda, and Zeria Pharmaceutical; **V. Jairath** has received consulting/advisory board fees from: AbbVie, Alimentiv, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris Pharmaceuticals, AstraZeneca, Avoro Capital, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, Endpoint Health, Entera, Ferring Pharmaceuticals, Flagship Pioneering, Fresenius Kabi, Galapagos NV, Gilde Healthcare, GlaxoSmithKline, Genentech, Gilead Sciences, Innomar, JAMP, Janssen, Merck, Metacrine, Mylan, Pandion Therapeutics, Pendopharm, Pfizer, Prometheus Biosciences, Protagonist Therapeutics, Reistone Biopharma, Roche, Roivant Sciences, Sandoz, SCOPE, Second Genome, Sorriso Pharmaceuticals, Takeda, TD Securities, Teva, Topivert, Ventyx Biosciences, and Vividion Therapeutics; and speaker's fees from: AbbVie, Bristol Myers Squibb, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos NV, Janssen, Pfizer, Shire, and Takeda

Disclosures (2/2)

- **J. Kierkus** has received speaker's fees, advisory board fees, and research funding from: Celltrion, Eli Lilly and Company, and Nestlé; **L. Peyrin-Biroulet** has received personal fees from: AbbVie, Allergan, Alma Therapeutics, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion Healthcare, Eli Lilly and Company, Enterome, Entera, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos NV, Genentech, Gilead Sciences, Hikma, InDex Pharmaceuticals, Inotrem, Janssen, Merck Sharp & Dohme, Mylan, Nestlé, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance, Tillots Pharma AG, and Vifor Pharma; received grants from: AbbVie, Merck Sharp & Dohme, and Takeda; and holds stock options in: CTMA; **B. Siegmund** has been a consultant and/or speaker for: AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim, CED Service, Celgene, Dr. Falk Pharma, Eli Lilly and Company, Ferring Pharmaceuticals, Galapagos NV, Janssen, Novartis, Pfizer, Prometheus Therapeutics, and Takeda; **S. M. Bragg, W. Crandall, T. Hunter Gible, Z. Lin, M. U. Lopes, N. Morris,** and **H. Carlier** are employees and shareholders of: Eli Lilly and Company; **B. E. Sands** has received fees for consulting/speaking from: AbbVie, Abivax, Aclaris Therapeutics, Adiso Therapeutics, AgomAb Therapeutics, Alfasigma, Alimentiv, Amgen, AMT, AnaptysBio, Arena Pharmaceuticals, Artizan Biosciences, AstraZeneca, Biora Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Calibr, Celltrion, ClostraBio, Connect Biopharma, Cytoki Pharma, EcoR1 Capital, Eli Lilly and Company, Entera, Equilium, Evommune, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos NV, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Imhotex, Immunic Therapeutics, ImmunityX Pharma, InDex Pharmaceuticals, Innovation Pharmaceuticals, Janssen, Janssen Biotech, Janssen Pharmaceutica NV, Janssen Research and Development, Janssen Scientific Affairs, Janssen-Cilag, Johnson & Johnson, Kaleido, Kyowa Kirin, Merck, Microba, Microbiotica, MiroBio, Morphic Therapeutic, MRM Health NV, Pfizer, Progenity, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Televant, Teva, TLL Pharmaceutical, VectivBio, and Ventyx Biosciences; received research support from: Bristol Myers Squibb, Janssen, Merck, Pfizer, Prometheus Biosciences, and Takeda; received speaker's fees from: AbbVie, Abivax, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Pfizer, and Takeda; other support: AbbVie, Abivax, Alimentiv, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Pfizer, and Takeda; and holds stock options/shares in: Ventyx Biosciences
- Medical writing assistance was provided by Tiffani Mungoven, PhD, and Alice Carruthers, PhD, of ProScribe – Envision Pharma Group, and was funded by Eli Lilly and Company

Background and Objective

Background

- Mirikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) that inhibits anti-interleukin (IL)-23 by binding to an epitope on the p19 subunit
- Mirikizumab is approved for the treatment of moderate to severe ulcerative colitis (UC) and is under development for Crohn's disease (CD)^{1,2}
- VIVID-1 is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled, treat-through study evaluating the efficacy and safety of mirikizumab in patients with moderate to severe active CD

Objective


- To report the primary efficacy and safety of mirikizumab compared with placebo up to Week 52 from the Phase 3 VIVID-1 study in patients with moderate to severe CD

1. OMVOH [Summary of Product Characteristics]. The Netherlands: Eli Lilly Nederland B.V., 2023. 2. Sands BE, et al. *Gastroenterology*. 2022;162:495-508.

VIVID-1 Study Design and Key Entry Criteria

Key Entry Criteria

- Adults aged ≥ 18 and ≤ 80 years
- Diagnosis of CD or fistulizing CD for ≥ 3 months
- Average daily liquid/soft stool frequency (SF) ≥ 4 and/or average daily abdominal pain (AP) ≥ 2
- Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥ 7 (or ≥ 4 for patients with isolated ileal disease)
- Inadequate response, loss of response, or intolerant to conventional or biologic therapy



^a Number of patients in the Safety Population; ^b Single dose; ^c Placebo was administered IV and SC from Weeks 8 to 20; otherwise administered IV at Weeks 0 and 4; from Week 24, PBO was administered SC only; ^d Responders by PRO at W12 of VIVID-1, defined as having achieved $\geq 30\%$ decrease in loose SF and/or AP, with neither score higher than baseline
 AP=abdominal pain; CD=Crohn's disease; CDAI=Crohn's Disease Activity Index; E=endoscopy; IV=intravenous; MIRI=mirikizumab; NR=non-responder; PBO=placebo; PRO=Patient Reported Outcome (2 of the patient-reported items of the CDAI [SF and AP]); Q4W=every 4 weeks; Q8W=every 8 weeks; R=responder; SC=subcutaneous; SF=stool frequency; USTE=ustekinumab; W=Week

Efficacy Endpoints

- Co-primary composite endpoints assessed superiority of mirikizumab over placebo^a:
 - Clinical response by PRO^b at Week 12 and endoscopic response by SES-CD at Week 52
 - Clinical response by PRO^b at Week 12 and Crohn's Disease Activity Index (CDAI) clinical remission at Week 52
- Major secondary endpoints vs. placebo:
 - Endoscopic response by SES-CD at Week 12
 - Endoscopic response by SES-CD at Week 52
 - Endoscopic remission by SES-CD at Week 12
 - Clinical remission by CDAI at Week 12
 - Clinical remission by CDAI at Week 52
 - Clinical response by PRO at Week 12
 - Clinical response by PRO at Week 12 and clinical remission by PRO at Week 52
 - Clinical response by PRO at Week 12 and corticosteroid-free remission at Week 52
 - Clinical response by PRO at Week 12 and endoscopic remission by SES-CD at Week 52

^a Both co-primary composite endpoints needed to be met to demonstrate superiority of mirikizumab over placebo; ^b PRO=Patient Reported Outcome (2 of the patient-reported items of the CDAI [SF and AP])

Note: The efficacy of mirikizumab in comparison to ustekinumab is presented in: Jairath V, et al. Presented at: ECCO 2024. Presentation number OP35
AP=abdominal pain; PRO=Patient Reported Outcome (2 of the patient-reported items of the CDAI [SF and AP]); SES-CD=Simple Endoscopic Score for Crohn's Disease; SF=stool frequency

Statistical Analysis

- Efficacy analyses were performed using the primary analysis set (patients from the mITT population who had baseline SES-CD ≥ 7 [or ≥ 4 for isolated ileal disease])
- Safety analyses were performed using the mITT population (patients who took ≥ 1 dose of the study intervention)
- Unless otherwise specified, all Week 52 endpoints were defined as a composite of Week 12 clinical response by PRO and the respective Week 52 endpoint
 - Treat-through analysis shows Week 52 results for mirikizumab, regardless of Week 12 clinical response by PRO^a
- Co-primary composite endpoints and major secondary endpoints were multiplicity-controlled
- Comparisons between mirikizumab and placebo were performed using the Cochran-Mantel-Haenszel test in all patients and by Fisher exact test in the subgroups (no prior biologic failure and prior biologic failure)^b
 - Non-responder imputation was used for missing data

^a Patients who received placebo who did not achieve a clinical response by PRO at Week 12 were considered non-responders at Week 52; ^b Prior biologic failure was defined as inadequate response, loss of response, or intolerance to ≥ 1 biologic medication approved for the treatment of CD

CD=Crohn's disease; CDAI=Crohn's Disease Activity Index; mITT=modified Intent-to-Treat; PRO=Patient Reported Outcome (2 of the patient-reported items of the CDAI [SF and AP]); SES-CD=Simple Endoscopic Score for Crohn's disease

Patient Demographics and Baseline Characteristics


Characteristic	PBO (N=199)	MIRI (N=579)
Age, years	36.3 (12.7)	36.0 (13.2)
Male, n (%)	118 (59.3)	332 (57.3)
Weight, kg	69.6 (19.0)	68.0 (18.3)
BMI, kg/m²	23.8 (5.8)	23.2 (5.4)
Duration of CD, years	7.8 (7.4)	7.4 (8.2)
Baseline CDAI	318.9 (86.2)	323.1 (85.8)
SF daily average	5.8 (3.2)	5.7 (3.0)
AP daily average	2.1 (0.6)	2.1 (0.6)
SES-CD total score	13.1 (6.0)	13.5 (6.6)
Disease location, n (%)		
Ileum only	19 (9.5)	65 (11.2)
Colon only	77 (38.7)	225 (38.9)
Ileum and colon	103 (51.8)	289 (49.9)
Corticosteroid use, n (%)	58 (29.1)	177 (30.6)
Immunomodulator use, n (%)	58 (29.1)	146 (25.2)
Prior biologic failure, n (%)	97 (48.7)	281 (48.5)
Number of failed biologics, n (%)		
None	102 (51.3)	298 (51.5)
1	66 (33.2)	175 (30.2)
≥2	31 (15.6)	106 (18.3)

Note: Data are mean (SD) unless stated otherwise; Primary Analysis Set population

AP=abdominal pain; BMI=body mass index; CD=Crohn's disease; CDAI=Crohn's Disease Activity Index; MIRI=mirikizumab; PBO=placebo; SD=standard deviation; SES-CD=Simple Endoscopic Score for Crohn's disease; SF=stool frequency

A Greater Proportion of Patients Achieved the Co-Primary Endpoints With Mirikizumab vs. Placebo (1/2)

Clinical Response by PRO at Week 12 and Endoscopic Response by SES-CD at Week 52




^a Primary Analysis Set

Notes: PRO clinical response was defined as $\geq 30\%$ decrease in SF and/or AP, with neither score worse than baseline; endoscopic response was defined as $\geq 50\%$ reduction from baseline in SES-CD total score. Δ is the risk difference between the groups indicated and is adjusted for covariates (biologic-failed status [yes or no], baseline SES-CD total score [<12 or ≥ 12], and either baseline SF ≥ 7 and/or baseline AP ≥ 2.5 [yes or unknown/no]) for the analysis of all patients and unadjusted for the subgroup analysis

AP=abdominal pain; CDAI=Crohn's Disease Activity Index; CI=confidence interval; MIRI=mirikizumab; NRI=non-responder imputation; PBO=placebo; PRO=Patient Reported Outcome (2 of the patient-reported items of the CDAI [SF and AP]); SES-CD=Simple Endoscopic Score for Crohn's Disease; SF=stool frequency


A Greater Proportion of Patients Achieved the Co-Primary Endpoints With Mirikizumab vs. Placebo (2/2)

Clinical Response by PRO at Week 12 and Clinical Remission by CDAI at Week 52



^a Primary Analysis Set
Notes: PRO clinical response was defined as ≥30% decrease in SF and/or AP, with neither score worse than baseline; CDAI clinical remission was defined as CDAI total score <150. Δ is the risk difference between the groups indicated and is adjusted for covariates (biologic-failed status [yes or no], baseline SES-CD total score [<12 or ≥12], and either baseline SF ≥7 and/or baseline AP ≥2.5 [yes or unknown/no]) for the analysis of all patients and unadjusted for the subgroup analysis
AP=abdominal pain; CDAI=Crohn’s Disease Activity Index; CI=confidence interval; MIRI=mirikizumab; NRI=non-responder imputation; PBO=placebo; PRO=Patient Reported Outcome (2 of the patient-reported items of the CDAI [SF and AP]); SES-CD=Simple Endoscopic Score for Crohn’s Disease; SF=stool frequency


A Greater Proportion of Patients Achieved All Week 12 Major Secondary Endpoints With Mirikizumab vs. Placebo



Notes: PRO clinical response was defined as $\geq 30\%$ decrease in SF and/or AP, with neither score worse than baseline; endoscopic response was defined as $\geq 50\%$ reduction from baseline in SES-CD total score; CDAI clinical remission was defined as CDAI total score < 150 ; PRO clinical remission was defined as unweighted daily average SF ≤ 3 (per Bristol Stool Scale Category 6 or 7) and unweighted daily average AP ≤ 1 , with neither score worse than baseline; endoscopic remission was defined as SES-CD total score ≤ 4 , a ≥ 2 -point reduction from baseline, and no subscore > 1 in any individual variable. Δ is the risk difference between the groups indicated and is adjusted for covariates (biologic-failed status [yes or no], baseline SES-CD total score [< 12 or ≥ 12], and either baseline SF ≥ 7 and/or baseline AP ≥ 2.5 [yes or unknown/no]) for the analysis of all patients

AP=abdominal pain; CDAI=Crohn's Disease Activity Index; CI=confidence interval; CS=corticosteroid; MIRI=mirikizumab; NRI=non-responder imputation; PBO=placebo; PRO=Patient Reported Outcome (2 of the patient-reported items of the CDAI [SF and AP]); SES-CD=Simple Endoscopic Score for Crohn's Disease; SF=stool frequency; TT=treat-through; W=Week

A Greater Proportion of Patients Achieved All Week 52 Major Secondary Endpoints With Mirikizumab vs. Placebo



Notes: Treat-through reflects the Week 52 mirikizumab endpoint result, regardless of response status at Week 12. Composite endpoints were defined as a composite of Week 12 PRO clinical response and the respective Week 52 endpoint. PRO clinical response was defined as ≥30% decrease in SF and/or AP, with neither score worse than baseline; endoscopic response was defined as ≥50% reduction from baseline in SES-CD total score; CDAI clinical remission was defined as CDAI total score <150; PRO clinical remission was defined as unweighted daily average SF ≤3 (per Bristol Stool Scale Category 6 or 7) and unweighted daily average AP ≤1, with neither score worse than baseline; endoscopic remission was defined as SES-CD total score ≤4, a ≥2-point reduction from baseline, and no subscore >1 in any individual variable. Δ is the risk difference between the groups indicated and is adjusted for covariates (biologic-failed status [yes or no], baseline SES-CD total score [<12 or ≥ 12], and either baseline SF ≥ 7 and/or baseline AP ≥ 2.5 [yes or unknown/no]) for the analysis of all patients

AP=abdominal pain; CDAI=Crohn’s Disease Activity Index; CI=confidence interval; CS=corticosteroid; MIRI=mirikizumab; NRI=non-responder imputation; PBO=placebo; PRO=Patient Reported Outcome (2 of the patient-reported items of the CDAI [SF and AP]); SES-CD=Simple Endoscopic Score for Crohn’s Disease; SF=stool frequency; W=Week

Overall Safety During The Week 52 Treatment Period Was Consistent With the Known Safety Profile of Mirikizumab

Event, n (%) [EAIR]	PBO ^a (N=211) PYE=119.5	MIRI (N=630) PYE=593.6	Event, n (%) [EAIR]	PBO ^a (N=211) PYE=119.5	MIRI (N=630) PYE=593.6
TEAE	154 (73.0) [291.8]	495 (78.6) [201.9]	Opportunistic infection^d	0	7 (1.1) [1.2]
Common TEAEs (>5% of patients)			Malignancy	1 (0.5) [0.8]	2 (0.3) [0.3]
COVID-19	29 (13.7) [26.4]	104 (16.5) [19.3]	Basal cell carcinoma	1 (0.5) [0.8]	1 (0.2) [0.2]
Anaemia	14 (6.6) [12.2]	42 (6.7) [7.4]	Breast cancer	0	1 (0.2) [0.2]
Arthralgia	11 (5.2) [9.6]	41 (6.5) [7.2]	MACE (adjudicated and confirmed)	2 (0.9) [1.7]	0
Headache	9 (4.3) [7.8]	41 (6.5) [7.2]	VTE^e	1 (0.5) [0.8]	0
Upper respiratory tract infection	9 (4.3) [7.8]	38 (6.0) [6.7]	Hepatic Laboratory		
Nasopharyngitis	9 (4.3) [7.7]	36 (5.7) [6.3]	ALT ≥3x ULN	0	12 (1.9) [2.0]
Diarrhoea	10 (4.7) [8.6]	35 (5.6) [6.1]	≥5x ULN	0	3 (0.5) [0.5]
Serious adverse events	36 (17.1) [32.5]	65 (10.3) [11.5]	AST ≥3x ULN	2 (1.0) [1.7]	9 (1.4) [1.5]
Serious infection	6 (2.8) [5.1]	14 (2.2) [2.4]	≥5x ULN	0	2 (0.3) [0.3]
Death	1 (0.5) ^b [0.8]	0 ^c	ALP ≥2x ULN	2 (1.0) [1.7]	7 (1.1) [1.2]

^a For patients randomized to PBO, only the exposure period to PBO is included; ^b 35-year-old male patient who died due to pulmonary embolism; ^c One additional 23-year-old male placebo non-responder patient who switched to mirikizumab after Week 12 died due to worsening of CD; ^d Most opportunistic infections were herpes zoster and 1 *Candida*; ^e One pulmonary embolism and no cases of deep venous thrombosis. Notes: Patients who were randomly assigned to PBO and were non-responders at Week 12 subsequently switched to MIRI treatment. Data from these participants after Week 12 are not included in the Week 0-52 analysis

ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CD=Crohn's disease; MACE=major adverse cardiovascular event; MIRI=mirikizumab; PBO=placebo; TB=total bilirubin; TEAE=treatment-emergent adverse event; ULN=upper limit of normal; VTE=venous thrombotic event


Conclusions

- In this Phase 3 CD study, mirikizumab demonstrated statistically significant and clinically meaningful improvements in both co-primary composite endpoints and all major secondary endpoints compared with placebo
- Response rates and effect sizes were robust and similar between the subgroups of patients with prior biologic failure and without prior biologic failure
- Mirikizumab demonstrated an acceptable safety profile in patients with moderate to severe CD that was consistent with the known safety profile in patients with moderate to severe UC¹


1. D'Haens G, et al. *N Engl J Med*. 2023;388:2444-2455.
CD=Crohn's disease; UC=ulcerative colitis

Implications of Different Study Designs on Calculating the Proportion of Patients Achieving W52 Endpoints


Treat-Through Study With Composite Endpoint



Treat-Through Study Without W12 Response Requirement



Post hoc Exploratory Analysis Evaluating W52 Response Among Induction Responders Only



- This example shows a range of approximately 20% depending on analysis type
- There are profound limitations comparing outcomes across Phase 3 trials with different study designs

CDAI=Crohn's Disease Activity Index; MIRI=mirikizumab; PRO=Patient Reported Outcome (2 of the patient-reported items of the CDAI [SF and AP]); pts=patients; W=Week